News | November 11, 2014

Zilver PTX Drug-Eluting Stent Study Data Show Continued Patency at Five Years

Simultaneous studies in the United States and Japan indicated favorable results for patients with peripheral arterial disease

November 11, 2014 — Five-year results from the largest and longest-running clinical trial of a drug-eluting stent for treating peripheral arterial disease (PAD) confirmed long-term patency for patients treated with Zilver PTX.

The results were presented by Michael Dake, M.D., of Stanford University, at the 2014 Vascular Interventional Advances (VIVA) meeting.

Data from the Zilver PTX Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease showed five-year primary patency of 66.4 percent in the superficial femoral artery (SFA) for patients treated with Cook’s paclitaxel-eluting stent. This compares to 43.4 percent patency for patients with balloon angioplasty or provisional bare metal stent placement.

“At five years, Zilver PTX demonstrated a 48 percent reduction in reintervention and a 41 percent reduction in restenosis compared to standard care,” Dake told the VIVA audience. “Five-year data for Zilver PTX versus bare metal stenting confirm a sustained benefit for the paclitaxel-eluting stent. Zilver PTX continues to show benefit through five years with no late catch-up.”

The Zilver PTX Randomized Trial of Paclitaxel-Eluting Stents for Femoropoliteal Artery Disease was a 479-patient multicenter, prospective, randomized study. It was designed to evaluate the PTX stent as a treatment for PAD in the SFA.

One-year post-market surveillance (PMS) study data from Japanese patients who received the Zilver PTX drug-eluting stent confirmed the benefits of the device at 12 months, researchers announced. Japanese researchers presented the PMS study results at the VIVA meeting in Las Vegas. This was the first time the study has been presented in the United States.

The PMS study was based in Japan and presented at VIVA by Hiroyoshi Yokoi, M.D., of Fukuoka Sanno Hospital. It included 907 patients with PAD treated at 95 institutions with Zilver PTX. Of those, 802 were eligible for 12-month follow up. After one year, 91.4 percent of the patients in the follow-up group did not need target lesion revascularization (TLR) of the SFA. The 84.8 percent primary patency result in the PMS study is similar to results from earlier Zilver PTX studies.

The patients studied were real-world cases, many of whom had more severe peripheral arterial disease than patients in the randomized control trial (RCT) for Zilver PTX.

“Many of the Japanese PMS patients’ lesions were more complex, with longer stenosed segments, more in-stent restenosis and fewer patent runoff vessels, compared to the RCT patient cohort,” Yokoi said. “Yet the results were quite favorable even in the more complex lesion sub-group.” Complex lesion sub-group results at 12 months showed 88.3 percent freedom from TLR and 81 percent primary patency.

Zilver PTX is the only drug-eluting stent approved in Japan for treating PAD. It has been approved for use in the European Union since August 2009 and the United States and Japan since 2012. Since its release, the stent has been used to treat more than 25,000 patients in North America, Europe, Asia, South America, Australia and New Zealand.

For more information: www.cookmedical.com

 

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init